Navigation Links
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Date:3/31/2008

ts, or to any ACE inhibitor or for patients taking LOTREL, amlodipine. Do not take the benazepril and HCTZ combination if you have a history of reduced urine output, or have allergic reactions to certain drugs known as sulfonamides and tell your doctor if you have liver problems, lupus or if you take lithium. Your doctor or pharmacist can give you a complete list of the ingredients in LOTREL or the benazepril and HCTZ combination.

In rare cases with LOTREL or the benazepril and HCTZ combination, a potentially life-threatening allergic reaction (swelling of the mouth and throat) can occur. This potentially dangerous swelling of the mouth and throat has been reported more often in African American patients receiving ACE inhibitors than in non-African American patients.

The most serious side effect with LOTREL and the benazepril and HCTZ combination is low blood pressure.

The most common side effects in patients taking LOTREL and the benazepril and HCTZ combination include cough, dizziness, and headache, additionally with the benazepril and HCTZ combination fatigue and additionally with LOTREL, edema (swelling of the feet, ankles, legs, or hands).

Please see full prescribing information about Lotrel and Lotensin HCT at http://www.pharma.us.novartis.com or contact Christine Cascio at 862-778-8026 or christine.cascio@novartis.com. The combination doses of benazepril and HCTZ

40/12.5 mg and 40/25 mg used in this study were investigational and do not have approved prescribing information available.

About high blood pressure and treatment

High blood pressure increases a person's risk of experiencing a cardiovascular event. For example, it has been reported that the risk of heart attack and stroke doubles with every 20/10 mmHg increase in blood pressure, starting at 115/75 mmHg. Blood pressure treatment guidelines s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
4. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
5. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. New Drug Combination is Able to Eradicate Breast Metastases in Mice
9. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytRx Corporation (NASDAQ: CYTR ), ... today reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical development ... been very productive for CytRx. Enrollment in our ongoing ... soft tissue sarcoma (STS) continues on track to be ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Array BioPharma Inc. ... the fourth quarter and full year of its ... Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib ... 3, are on track for regulatory submissions in ... BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate ...
(Date:8/3/2015)... 2015 Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: ... Teper , will present live at VirtualInvestorConferences.com on August ...   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... where investors are invited to ask the company questions ... well as the association,s "virtual trade booth." If attendees ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2
... May 12 Huntington Bank (Nasdaq: HBAN ... to finance a $25 million electronic medical records ... care providers, Zanesville -based Genesis HealthCare System. The ... information system enabling Genesis to establish an EMR across its ...
... May 12 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, Inc. (Nasdaq: CBPO ... China , today announced that its,majority-owned subsidiary, Shandong Taibang Biological ... Health,Department to build two new plasma stations. , ... "This approval ...
Cached Medicine Technology:Huntington Financing Package Supports Major Regional Medical Center Electronic Medical Records Project 2China Biologic Products to Build Two New Plasma Stations in Shandong Province 2China Biologic Products to Build Two New Plasma Stations in Shandong Province 3China Biologic Products to Build Two New Plasma Stations in Shandong Province 4
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning Labels is ... Denver facility that will usher in a new standard of sticker and label-making ... more effectively meet its twin objectives of quality and quantity without compromising the ...
(Date:8/4/2015)... ... ... Following last month’s successful rollout of its client video series, ACE announces the ... Setting, and The Importance of PVI Accreditation. , In The Benefits of Cath ... Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las Vegas, NV, Chandan Devireddy, MD, ...
(Date:8/3/2015)... ... August 04, 2015 , ... ... Holt as a 2015-2016 inductee into the NAPW VIP Woman of the ... With more than 700,000 members and over 200 operating Local Chapters, NAPW is ...
(Date:8/3/2015)... ... August 04, 2015 , ... Keeping strong to their ... professionals, HomeCEUConnection.com today announced extra savings on Florida Physical Therapy continuing education ... big savings on Physical Therapy Flex packages by entering the promo ...
(Date:8/3/2015)... Indianapolis, Indiana (PRWEB) , ... August 03, 2015 ... ... ) throughout Livingston and Putnam counties. As a family owned and operated ... all septic matters. They are a leader in septic installations because of ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:Elite Online CE Provider Offers Discounted Flexible Packages to Meet Florida Physical Therapy Continuing Education Requirements 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3
... that has enhanced public understanding of biomedical researchWASHINGTON, ... (FBR) announced today it is accepting entries for ... The awards, named after FBR,s late chairman, ... reporting has enhanced public understanding of how the ...
... April 3 AstraZeneca (NYSE: AZN ) ... Drug Administration (FDA) posted to its web site -- ... 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The ... efficacy data provided in supplemental new drug applications (sNDA) ...
... researchers say , , FRIDAY, April 3 (HealthDay News) -- ... insights into multiple sclerosis and other afflictions of the ... looking into why pregnant cats on a special diet ... including paralysis and vision, University of Wisconsin-Madison researchers found ...
... stock jeopardize shareholder interests?TEQUESTA, Fla., April 3 In ... and the Board of Directors of Energy Partners, LTD ... (CCC), personally holding a quarter million shares as well ... concern over a proposed bond buyout of the company,s ...
... Pass Bill to Protect Patient Access WASHINGTON, April 3 ... osteoporosis testing and reduce the physical and economic burden ... "Medicare Fracture Prevention and Osteoporosis Testing Act of 2009," ... and Olympia Snowe (R-ME) introduced the Senate version and ...
... 3 First Choice Professionals, LLC., today announced the ... Health Integration Solution ( THIS ). ... has joined forces with TIBCO Software Inc. (Nasdaq: ... brokering, SOA integration, and complex event processing. The partnership ...
Cached Medicine News:Health News:Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 3Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 4Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 5Health News:Cat Food-Linked Illness Yields Clues to MS 2Health News:Access to Osteoporosis Testing for Americans in Jeopardy 2Health News:Access to Osteoporosis Testing for Americans in Jeopardy 3Health News:Access to Osteoporosis Testing for Americans in Jeopardy 4Health News:Access to Osteoporosis Testing for Americans in Jeopardy 5Health News:FCP Announces Total Healthcare Integration Solution (THIS) Powered by TIBCO 2
... device is a qualitative immunoassay ... inspect the,overdose usage of cocaine ... metabolite of,cocaine, in human urine ... 300 ng/mL. It is for ...
... test is an immunochromatography based one ... for qualitative determination of Benzodiazepines and ... a cut-off level of 300 ng/mL ... in the point of care location ...
... 2000, Applied Biosystems introduced the completely ... M 3100 Genetic Analyzer.,Now the innovative ... available in our new four-capillary ABI ... to-medium-throughput laboratory needs, the fully automated ...
... AcT diff2 delivers performance, ... office labs and smaller laboratories. ... that offers a small sample ... closed analysis modes, a wide ...
Medicine Products: